欣饴元

Xyone Biotech is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on developing next-generation therapies for metabolic diseases. The company specializes in multi-receptor agonists, particularly those targeting the GLP-1, GIP, and Glucagon receptors, to address conditions such as obesity, type 2 diabetes, and MASH. Its lead candidate, XY-01, is a triple agonist designed to optimize weight loss and metabolic health through a synergistic mechanism of action. Backed by prominent investors like Qiming Venture Partners and Sequoia China, Xyone Biotech leverages its proprietary peptide engineering platform to create highly potent and stable therapeutic candidates with improved pharmacological profiles.